These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24185435)

  • 1. Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
    Hussar DA; Ahmad A
    J Am Pharm Assoc (2003); 2013; 53(6):662-70. PubMed ID: 24185435
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluticasone-vilanterol combination approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
    Wolthers OD
    Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relvar Ellipta for asthma.
    Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial.
    Bar-Yoseph R; Gur M; Zuckerman S; Gut G; Hanna M; Toukan Y; Nir V; Masarweh K; Bentur L
    Basic Clin Pharmacol Toxicol; 2021 Nov; 129(5):369-375. PubMed ID: 34359097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.
    Vallejo-Aparicio LA; Molina J; Ojanguren I; Viejo Casas A; Huerta A; Svedsater H
    Eur J Health Econ; 2020 Feb; 21(1):7-17. PubMed ID: 31549255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.
    Chang V; Gray EL; Thomas PS
    Expert Rev Respir Med; 2016 Oct; 10(10):1069-78. PubMed ID: 27599692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.
    Calzetta L; Rinaldi B; Cazzola M; Matera MG
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):813-22. PubMed ID: 27253498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma.
    Gray EL; Chang V; Thomas PS
    Expert Rev Respir Med; 2016 Aug; 10(8):839-47. PubMed ID: 27221165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.
    Albertson TE; Bullick SW; Schivo M; Sutter ME
    Drug Des Devel Ther; 2016; 10():4047-4060. PubMed ID: 28008228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Once daily with a powder inhaler].
    Fath R
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049359
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.